Novartis Announces the Planned Acquisition of Advanced Accelerator Applications
Novartis announced that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Advanced Accelerator Applications (NASDAQ:AAAP) is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera® (177Lu-DOTATATE), a first-in-class RLT product for neuroendocrine tumors (NETs). Radiopharmaceuticals, such as Lutathera, are unique medicinal formulations containing radioisotopes which are used clinically for both diagnosis and therapy. The transaction would strengthen Novartis' oncology presence with both near-term product launches as well as a new technology platform with potential applications across a number of oncology early development programs.
NANETS2017 Registration Update
Dear NANETS Members and Colleagues,
We are so grateful to everyone interested in attending the 10th Annual NANETS Symposium, October 19-21, 2017 in Philadelphia, PA. We have exceeded last year by over 180 registrants.
For the first time ever, the annual NANETS Symposium has SOLD OUT. Due to hotel capacity rules and fire codes we unfortunately cannot accommodate any more registrants, including any walk-up registrations.
NANETS to Present Basic/Translational Science Investigator Award
The North American Neuroendocrine Tumor Society (NANETS) is pleased to announce the Neuroendocrine Tumor Research Foundation (NETRF) Board of Directors has approved funding for the Basic/Translational Science Investigator (BTSI) Award for 2017 presented by NANETS. The 2017 award will be announced at the NANETS 10th annual symposium, to be held October 19-21 in Philadelphia, PA.
The purpose of the BTSI Award is to encourage scientists at the end of their fellowship or beginning their faculty appointment to pursue basic and/or translational research focused on neuroendocrine tumors. The two-year award provides $50,000 in funding each year, which is directed to the investigator’s sponsoring institution. NETRF funds this award with the generous support of the Margie and Robert E. Petersen Foundation.